Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Determine if genotype-directed neoadjuvant chemoradiation, using information from the
thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging
in high risk patients compared to historical controls.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine if genotype-directed neoadjuvant chemoradiation, using information from the thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging in high risk patients compared to historical controls.
throughout trial participation
No
Benjamin Tan, M.D.
Principal Investigator
Washington University School of Medicine
United States: Institutional Review Board
02-0561
NCT00682786
October 2002
August 2010
Name | Location |
---|---|
Washington University School of Medicine | Saint Louis, Missouri 63110 |